|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GRPEL1 |
Gene summary for GRPEL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GRPEL1 | Gene ID | 80273 |
| Gene name | GrpE like 1, mitochondrial | |
| Gene Alias | GrpE | |
| Cytomap | 4p16.1 | |
| Gene Type | protein-coding | GO ID | GO:0006457 | UniProtAcc | Q9HAV7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 80273 | GRPEL1 | C06 | Human | Oral cavity | OSCC | 1.17e-11 | 1.86e+00 | 0.2699 |
| 80273 | GRPEL1 | C07 | Human | Oral cavity | OSCC | 2.35e-02 | 9.71e-01 | 0.2491 |
| 80273 | GRPEL1 | C08 | Human | Oral cavity | OSCC | 2.07e-21 | 5.85e-01 | 0.1919 |
| 80273 | GRPEL1 | C09 | Human | Oral cavity | OSCC | 1.53e-07 | 4.11e-01 | 0.1431 |
| 80273 | GRPEL1 | LN22 | Human | Oral cavity | OSCC | 2.11e-07 | 9.82e-01 | 0.1733 |
| 80273 | GRPEL1 | LN38 | Human | Oral cavity | OSCC | 3.56e-02 | 4.56e-01 | 0.168 |
| 80273 | GRPEL1 | LN46 | Human | Oral cavity | OSCC | 1.10e-12 | 7.51e-01 | 0.1666 |
| 80273 | GRPEL1 | LP15 | Human | Oral cavity | LP | 5.73e-08 | 1.25e+00 | 0.2174 |
| 80273 | GRPEL1 | SYSMH1 | Human | Oral cavity | OSCC | 7.43e-12 | 3.76e-01 | 0.1127 |
| 80273 | GRPEL1 | SYSMH2 | Human | Oral cavity | OSCC | 6.45e-26 | 1.22e+00 | 0.2326 |
| 80273 | GRPEL1 | SYSMH3 | Human | Oral cavity | OSCC | 1.65e-37 | 1.26e+00 | 0.2442 |
| 80273 | GRPEL1 | SYSMH4 | Human | Oral cavity | OSCC | 4.86e-03 | 2.29e-01 | 0.1226 |
| 80273 | GRPEL1 | SYSMH5 | Human | Oral cavity | OSCC | 6.88e-20 | 6.64e-01 | 0.0647 |
| 80273 | GRPEL1 | SYSMH6 | Human | Oral cavity | OSCC | 1.20e-06 | 4.30e-01 | 0.1275 |
| 80273 | GRPEL1 | GSM5252130_BPH340PrGF_Via | Human | Prostate | BPH | 6.89e-13 | 5.92e-01 | -0.1972 |
| 80273 | GRPEL1 | GSM5252133_BPH389PrSF | Human | Prostate | BPH | 1.09e-02 | 6.84e-01 | -0.2027 |
| 80273 | GRPEL1 | 047563_1562-all-cells | Human | Prostate | BPH | 2.11e-16 | -2.91e-01 | 0.0791 |
| 80273 | GRPEL1 | 052097_1595-all-cells | Human | Prostate | BPH | 2.57e-03 | -2.17e-01 | 0.0972 |
| 80273 | GRPEL1 | 052099_1652-all-cells | Human | Prostate | BPH | 3.64e-03 | -2.68e-01 | 0.1038 |
| 80273 | GRPEL1 | Dong_P1 | Human | Prostate | Tumor | 3.16e-17 | -3.25e-01 | 0.035 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0072594110 | Esophagus | ESCC | establishment of protein localization to organelle | 311/8552 | 422/18723 | 3.02e-32 | 2.13e-29 | 311 |
| GO:0006605111 | Esophagus | ESCC | protein targeting | 229/8552 | 314/18723 | 4.93e-23 | 1.01e-20 | 229 |
| GO:0006457110 | Esophagus | ESCC | protein folding | 163/8552 | 212/18723 | 1.13e-20 | 1.74e-18 | 163 |
| GO:0006839110 | Esophagus | ESCC | mitochondrial transport | 187/8552 | 254/18723 | 8.35e-20 | 9.81e-18 | 187 |
| GO:0072655110 | Esophagus | ESCC | establishment of protein localization to mitochondrion | 97/8552 | 120/18723 | 2.17e-15 | 1.33e-13 | 97 |
| GO:0070585110 | Esophagus | ESCC | protein localization to mitochondrion | 100/8552 | 125/18723 | 2.96e-15 | 1.77e-13 | 100 |
| GO:001703818 | Esophagus | ESCC | protein import | 149/8552 | 206/18723 | 5.90e-15 | 3.31e-13 | 149 |
| GO:0006626110 | Esophagus | ESCC | protein targeting to mitochondrion | 81/8552 | 100/18723 | 3.60e-13 | 1.67e-11 | 81 |
| GO:00718069 | Esophagus | ESCC | protein transmembrane transport | 47/8552 | 59/18723 | 9.02e-08 | 1.51e-06 | 47 |
| GO:1990542110 | Esophagus | ESCC | mitochondrial transmembrane transport | 72/8552 | 102/18723 | 2.94e-07 | 4.23e-06 | 72 |
| GO:00650026 | Esophagus | ESCC | intracellular protein transmembrane transport | 40/8552 | 51/18723 | 1.76e-06 | 2.08e-05 | 40 |
| GO:00447433 | Esophagus | ESCC | protein transmembrane import into intracellular organelle | 29/8552 | 36/18723 | 1.91e-05 | 1.67e-04 | 29 |
| GO:00301503 | Esophagus | ESCC | protein import into mitochondrial matrix | 16/8552 | 20/18723 | 1.85e-03 | 8.40e-03 | 16 |
| GO:00064577 | Liver | Cirrhotic | protein folding | 114/4634 | 212/18723 | 9.23e-20 | 2.31e-17 | 114 |
| GO:007259412 | Liver | Cirrhotic | establishment of protein localization to organelle | 189/4634 | 422/18723 | 1.01e-19 | 2.45e-17 | 189 |
| GO:00066057 | Liver | Cirrhotic | protein targeting | 148/4634 | 314/18723 | 3.86e-18 | 6.20e-16 | 148 |
| GO:00068397 | Liver | Cirrhotic | mitochondrial transport | 112/4634 | 254/18723 | 1.03e-11 | 6.66e-10 | 112 |
| GO:00705857 | Liver | Cirrhotic | protein localization to mitochondrion | 65/4634 | 125/18723 | 4.91e-11 | 2.77e-09 | 65 |
| GO:00726557 | Liver | Cirrhotic | establishment of protein localization to mitochondrion | 63/4634 | 120/18723 | 5.70e-11 | 3.19e-09 | 63 |
| GO:00066267 | Liver | Cirrhotic | protein targeting to mitochondrion | 53/4634 | 100/18723 | 1.19e-09 | 5.27e-08 | 53 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GRPEL1 | SNV | Missense_Mutation | rs370293338 | c.511N>A | p.Asp171Asn | p.D171N | Q9HAV7 | protein_coding | tolerated(0.16) | benign(0.123) | TCGA-C8-A8HR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
| GRPEL1 | insertion | In_Frame_Ins | novel | c.374_375insCCTCTCATGGAGATCCTTGCCGCTGAGGCAAGCATG | p.Val125_Pro126insLeuSerTrpArgSerLeuProLeuArgGlnAlaCys | p.V125_P126insLSWRSLPLRQAC | Q9HAV7 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| GRPEL1 | insertion | Nonsense_Mutation | novel | c.226_227insTGCATATTTACAGTAGGAATTAAAGATTTGTTTAGCTACC | p.Glu76ValfsTer8 | p.E76Vfs*8 | Q9HAV7 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| GRPEL1 | SNV | Missense_Mutation | rs766058514 | c.610C>T | p.Arg204Cys | p.R204C | Q9HAV7 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GRPEL1 | SNV | Missense_Mutation | c.92C>T | p.Thr31Met | p.T31M | Q9HAV7 | protein_coding | deleterious(0.02) | possibly_damaging(0.569) | TCGA-F4-6856-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | CR | |
| GRPEL1 | SNV | Missense_Mutation | c.580N>T | p.Val194Phe | p.V194F | Q9HAV7 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| GRPEL1 | SNV | Missense_Mutation | novel | c.608G>A | p.Gly203Glu | p.G203E | Q9HAV7 | protein_coding | tolerated(0.26) | benign(0.163) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| GRPEL1 | SNV | Missense_Mutation | novel | c.328G>A | p.Asp110Asn | p.D110N | Q9HAV7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| GRPEL1 | SNV | Missense_Mutation | novel | c.608G>T | p.Gly203Val | p.G203V | Q9HAV7 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GRPEL1 | SNV | Missense_Mutation | c.132N>T | p.Met44Ile | p.M44I | Q9HAV7 | protein_coding | tolerated(0.19) | benign(0) | TCGA-AP-A0LD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |